Menu

BeyondSPX has rebranded as EveryTicker. We now operate at everyticker.com, reflecting our coverage across nearly all U.S. tickers. BeyondSPX has rebranded as EveryTicker.

Price Performance Heatmap

5Y Price (Market Cap Weighted)

All Stocks (12)

Company Market Cap Price
NVO Novo Nordisk A/S
At-home administration devices (auto-injector devices) for GLP-1 therapies are part of Novo Nordisk’s delivery platform.
$278.30B
$62.34
+9.15%
BDX Becton, Dickinson and Company
BD develops auto‑injector devices (wearable injectors) for home/at‑home administration of biologics.
$59.36B
$207.11
-0.60%
TAK Takeda Pharmaceutical Company Limited
ENTYVIO Pen demonstrates the use of auto-injector devices for at-home administration of biologics.
$50.48B
$16.16
-1.04%
WST West Pharmaceutical Services, Inc.
Auto-Injector Devices are a key product category in West's GLP-1 and other injectable platforms.
$18.68B
$259.81
-7.01%
ROIV Roivant Sciences Ltd.
Auto-injector devices enabling at-home administration for IMVT-1402, fitting Auto-Injector Devices.
$15.80B
$23.11
-0.79%
HALO Halozyme Therapeutics, Inc.
Halozyme is expanding its portfolio of auto-injector devices to enable at-home/self-administration of therapies.
$8.33B
$71.21
-0.85%
ATR AptarGroup, Inc.
Aptar has auto-injector devices/platforms for at-home administration of injectable therapies.
$8.22B
$124.71
-0.32%
STVN Stevanato Group S.p.A.
Develops and manufactures Auto-Injector Devices for at-home/self-administration of injectable therapies.
$5.98B
$19.79
-5.76%
AMRX Amneal Pharmaceuticals, Inc.
DHE autoinjector (Brekiya) approval signals involvement in auto-injector device delivery systems.
$4.21B
$13.40
+1.63%
KE Kimball Electronics, Inc.
Auto-injector devices represent a differentiated medical device assembly capability.
$746.66M
$30.75
-2.01%
SCPH scPharmaceuticals Inc.
Auto-Injector Devices reflect the SCP-111 autoinjector program for at-home administration.
$299.33M
$5.67
ASRT Assertio Holdings, Inc.
Otrexup is an auto-injector device, fitting the Auto-Injector Devices category.
$73.66M
$11.47
+3.05%

Loading company comparison...

Loading research report...

STVN Stevanato Group S.p.A.

Stevanato Group, Datwyler and LTS Device Technologies Announce Collaboration to Deliver 20‑mL Subcutaneous Therapies

Jan 17, 2026
BDX Becton, Dickinson and Company

BD Secures FDA 510(k) Clearance for EnCor EnCompass™ Breast Biopsy System

Jan 15, 2026
BDX Becton, Dickinson and Company

BDX Invests $110 Million to Expand U.S. Prefilled Syringe Production

Jan 14, 2026
WST West Pharmaceutical Services, Inc.

West Pharmaceutical Sells SmartDose 3.5 mL On‑Body Delivery System and Facilities to AbbVie for $112.5 Million

Jan 13, 2026
AMRX Amneal Pharmaceuticals, Inc.

Amneal Pharmaceuticals and KeifeRx Announce Research Collaboration and Option Agreement for Parkinson’s Disease Candidate KFRX06

Jan 09, 2026
NVO Novo Nordisk A/S

Amazon Pharmacy Expands Distribution of Novo Nordisk’s Oral Wegovy Weight‑Loss Pill

Jan 09, 2026
HALO Halozyme Therapeutics, Inc.

Halozyme and Takeda Announce Global Collaboration to Deliver Vedolizumab via ENHANZE® Technology

Jan 08, 2026
BDX Becton, Dickinson and Company

BD Reports First Phasix Mesh Prophylaxis Case in Greece, Advances PREVENT Trial Enrollment

Jan 05, 2026
HALO Halozyme Therapeutics, Inc.

Halozyme and Skye Bioscience Announce Collaboration to Develop Subcutaneous Nimacimab for Obesity

Jan 05, 2026
TAK Takeda Pharmaceutical Company Limited

Takeda and Protagonist File FDA NDA for Rusfertide, a First‑In‑Class Treatment for Polycythemia Vera

Jan 05, 2026
NVO Novo Nordisk A/S

Novo Nordisk Wins Supreme Court Patent Ruling in China, Securing Semaglutide Rights Ahead of 2026 Expiration

Dec 31, 2025
NVO Novo Nordisk A/S

Novo Nordisk Slashes Wegovy Prices in China to Counter Rising Generic Competition

Dec 29, 2025
NVO Novo Nordisk A/S

Novo Nordisk Receives FDA Approval for First Oral GLP‑1 Weight‑Loss Pill

Dec 23, 2025